X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Following oral administration, ADX48621 (dipraglurant) was rapidly absorbed and readily crossed the blood-brain barrier. In vivo, dipraglurant administration was found to dose-dependently impact the various NMS disease models.
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Master Fund Ltd.
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 26, 2022
Details:
Addex intends to use the net proceeds from this offering to advance its clinical and preclinical pipeline including development and commercialization of its lead asset ADX48621(dipraglurant).
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Armistice Master Fund LTV
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Financing July 22, 2022
Details:
ADX48621 (Dipraglurant (Immediate Release), as a novel orally available mGlu5 NAM, for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
ADX48621 (dipraglurant), is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM. It’s lead indication is levodopa induced dyskinesia associated with Parkinson’s disease, or PD-LID.
Lead Product(s): Dipraglurant
Therapeutic Area: Ophthalmology Product Name: ADX48621
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
The double-blind, randomized Phase 2a feasibility study will enroll 15 patients with blepharospasm. It is designed to assess the safety and tolerability of dipraglurant as well as explore its effects on the severity and frequency of blepharospasm signs and symptoms.
Lead Product(s): Dipraglurant
Therapeutic Area: Ophthalmology Product Name: ADX48621
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
Addex intends to use the net proceeds from the global offering, mainly to advance development of its portfolio of proprietary drug candidates based on its allosteric modulator development capabilities. These include dipraglurant for use in Parkinson's disease and dystonia.
Lead Product(s): Dipraglurant
Therapeutic Area: Neurology Product Name: ADX48621
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
